VEGF-targeted therapies were used in 12,802 patients, primarily for colorectal cancer (n = 6983; 55%), gynecological cancer (n = 1783; 14%), brain cancer (n = 1434; 11.2%), and lung cancer (n = 1141; 9%). This evidence concerns the gene VEGFA and lung carcinoma.